Skip to main content

Table 1 Demographics of Analysed Study Populations

From: Efficacy and safety of 0.05% micellar nano-particulate (MNP) cyclosporine ophthalmic emulsion in the treatment of moderate-to-severe keratoconjunctivitis sicca: a 12-week, multicenter, randomized, active-controlled trial

Treatment group

A

B

C

Safety population (N)

51

53

51

Sex (count): M/F (M%)

25/26 (49.0%)

27/26 (50.9%)

24/27 (47.1%)

Age (yrs):Mean (SD)

43.4 (11.9)

40.7 (15.1)

45.5 (13.7)

Range

21–69

19–77

19–67

ITT population (N)

48

49

48

Sex (count): M/F (M%)

24/24 (50.0%)

25/24 (51.0%)

23/25 (47.9%)

Age (yrs):Mean (SD)

43.4 (12.1)

40.7 (15.3)

46.3 (13.5)

Range

21–65

19–77

19–67

PP population (N)

30

32

28

Sex (count): M/F (M%)

15/15 (50.0%)

16/16 (50.0%)

12/16 (42.9%)

Age (yrs):Mean (SD)

43.6 (11.4)

40.0 (13.9)

44.6 (13.8)

Range

21–65

19–64

19–65